LabTurbo Biotech Corporation
LabTurbo Biotech Corporation engages in the research, manufacture, and sale of gene detection systems and kits in Taiwan, the United States, the Czech Republic, Spain, France, Israel, Singapore, the Philippines, and Malaysia. It serves hospitals. The company was founded in 2000 and is based in Taipei, Taiwan.
LabTurbo Biotech Corporation (7725) - Total Liabilities
Latest total liabilities as of June 2025: NT$85.23 Million TWD
Based on the latest financial reports, LabTurbo Biotech Corporation (7725) has total liabilities worth NT$85.23 Million TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
LabTurbo Biotech Corporation - Total Liabilities Trend (2021–2024)
This chart illustrates how LabTurbo Biotech Corporation's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
LabTurbo Biotech Corporation Competitors by Total Liabilities
The table below lists competitors of LabTurbo Biotech Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
FIRST PACIFIC (FPC.SG)
STU:FPC
|
Germany | €15.79 Billion |
|
AGP Ltd
KAR:AGP
|
Pakistan | PKRs15.81 Billion |
|
Rajoo Engineers Limited
NSE:RAJOOENG
|
India | ₹2.71 Billion |
|
TRINITY MIRROR
BE:MRR
|
Germany | €582.10 Million |
|
Bayn Group AB (publ)
MU:B39
|
Germany | €3.90 Billion |
Liability Composition Analysis (2021–2024)
This chart breaks down LabTurbo Biotech Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.89 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how LabTurbo Biotech Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for LabTurbo Biotech Corporation (2021–2024)
The table below shows the annual total liabilities of LabTurbo Biotech Corporation from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$76.13 Million | +15.33% |
| 2023-12-31 | NT$66.01 Million | -72.50% |
| 2022-12-31 | NT$240.03 Million | -21.11% |
| 2021-12-31 | NT$304.25 Million | -- |